A5026419465- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Palliative Care and End-of-Life Issues
- Tumors and Oncological Cases
- Ethics and Legal Issues in Pediatric Healthcare
- Pharmaceutical studies and practices
- Acute Lymphoblastic Leukemia research
- Chromatin Remodeling and Cancer
- Cardiac tumors and thrombi
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- Gastrointestinal Tumor Research and Treatment
- Adrenal Hormones and Disorders
- Cancer-related gene regulation
- Adolescent and Pediatric Healthcare
- Polyomavirus and related diseases
- Health Systems, Economic Evaluations, Quality of Life
- Pneumothorax, Barotrauma, Emphysema
Hospital for Sick Children
2020-2025
SickKids Foundation
2021-2024
University of Toronto
2021-2024
University College London
2023
Great Ormond Street Hospital
2023
Alberta Health Services
2021
Montreal Children's Hospital
2021
Public Health Agency of Canada
2021
Pediatric Oncology Group
2021
Université du Québec à Montréal
2021
We conducted integrative somatic-germline analyses by deeply sequencing 864 cancer-associated genes, complete genomes and transcriptomes for 300 mostly previously treated children adolescents/young adults with cancer of poor prognosis or rare tumors enrolled in the SickKids Cancer Sequencing (KiCS) program. Clinically actionable variants were identified 56% patients. Improved diagnostic accuracy led to modified management a subset. Therapeutically targetable (54% patients) unanticipated...
Background This retrospective multicenter study assessed the clinical, radiological and pathological presentation, treatment outcome of 26 patients with Ewing‐like sarcoma harboring BCOR‐CCNB3 gene fusion transcript. Tumor samples had been collected between 1994 April 2012. Procedure Eligibility criteria included assessment a transcript‐positive tumor after molecular analysis availability minimal clinical data. Radiological data were also retrieved when possible. Data analyzed by descriptive...
The causes of pediatric cancers' distinctiveness compared to adult-onset tumors the same type are not completely clear and fully explained by their genomes. In this study, we used an optimized multilevel RNA clustering approach derive molecular definitions for most childhood cancers. Applying method 13,313 transcriptomes, constructed a cancer atlas explore age-associated changes. Tumor entities were sometimes unexpectedly grouped due common lineages, drivers or stemness profiles. Some...
Abstract Based on characterization of both genomic and expression status WT1 CTNNB1 (β‐catenin) in a series 60 Wilms tumor samples, combined with genome‐wide profiling these tumors, normal mature fetal kidney controls, we show that WT1/β‐catenin was better classifier than / mutations. We present molecular data supporting the WNT pathway is involved classes, without alterations. In class alterations, identified overexpression 14 previously unreported target genes, including TWIST1 . protein...
Abstract The emerging use of immunotherapy for cancer treatment has led to a greater need characterizing markers response. Incorporating immune profiling tools into whole genome and transcriptome sequencing analysis (WGTA) pipelines facilitates the identification biomarkers response that may be used inform clinical trial design. Personalized OncoGenomics (POG) program enrolled >1,200 patients with advanced/metastatic cancers diverse histologies underwent WGTA, which allowed...
Sequencing of neuroblastoma (NB) tumors has revealed genetic alterations in genes involved DNA damage response (DDR) pathways. However, roles for specific DDR pediatric solid remain poorly understood. To address this, mutations the pathway including Brca2, Atm, and Palb2 were incorporated into an established zebrafish MYCN transgenic model (Tg(dbh:EGFP-MYCN)). These enhance NB formation metastasis result upregulation cell-cycle checkpoint repair signatures, revealing molecular...
We conducted a retrospective multi-centre study to assess the real-world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) chondrosarcoma (CS)/extra-skeletal mesenchymal CS (ESMC).After regulatory approval, data from patients with recurrent BT (11 institutions) were extracted CanSaRCC (Canadian Sarcoma Research Clinical Collaboration) database. Patient characteristics, treatment outcomes...
Abstract Cancer is the leading cause of disease-related death in children, adolescents, and young adults beyond newborn period North America. Improving survival rates for patients with hard-to-cure cancer remains a challenge. One approach that has gained particular traction ‘precision oncology’, whereby next-generation sequencing used to identify genomic or transcriptomic changes can help clarify diagnosis, refine prognosis, define an underlying genetic cause, unique treatment target...
The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval accessible clinical trials has led "out-of-trial" use innovative therapies. We conducted a retrospective analysis requests anticancer therapy Canadian tertiary centers patients less than 30 years old between 2013 2020.
To the editor, Neuroblastoma is most common extracranial solid tumor of childhood and encompasses a wide range clinical presentations related prognoses. Patients with high-risk neuroblastoma have poorest prognosis, 5-year survival rates approximately 50% [[1]Irwin M.S. Naranjo A. Zhang F.F. Cohn S.L. London W.B. Gastier-Foster J.M. et al.Revised Risk Classification System: A Report From Children's Oncology Group.J Clin Oncol. 2021; 39: 3229-3241https://doi.org/10.1200/JCO.21.00278Crossref...
Background: In developed countries, cancer remains the leading cause of pediatric death from illness after neonatal period. Objective: To describe end-of-life care characteristics children and adolescents with solid tumors (ST) or hematologic malignancies (HM) who died tumor progression in Île-de-France area. Methods: This is a regional, multicentric, retrospective review medical files all over 1-year Extensive data last 3 months life were collected. Results: A total 99 eligible patients at...
<h3>Background:</h3> The COVID-19 pandemic has had a major impact on access to health care resources. Our objective was estimate the of incidence childhood cancer in Canada. We also aimed compare proportion patients who enrolled clinical trials at diagnosis, presented with metastatic disease or an early death during first 9 months compared previous years. <h3>Methods:</h3> conducted observational study that included children younger than 15 years new diagnosis between March 2016 and November...
Little is known about care management for foreign patients in pediatric oncology European centers. We aimed to describe given children, adolescents, and young adults who came France cancer treatment, determine whether their geographical origin had an influence on decision making.We conducted a monocentric retrospective study all aged 0-25 years hospitalized at least one night Institut Curie (Paris, France) from 2009 2013. analyzed the potential advantages of receiving treatment as well...
Abstract Background: Neuroblastoma (NB) is the most common extra-cranial solid tumor in children and accounts for approximately 10% of childhood cancer deaths. Recently, next-generation sequencing patients enrolled SickKids Cancer Sequencing (KiCS) program revealed somatic germline alterations genes involved DNA damage response (DDR). Multiple pathogenic variants CHEK2 were detected with NB. Aims Methods: To better understand potential roles NB pathogenesis, we are modeling patient-derived...
Abstract Background: Neuroblastoma is a pediatric solid tumor that arises from neural crest-derived progenitor cells of the peripheral sympathetic nervous system (PSNS). patients display significant level genetic and phenotypic heterogeneity, with amplification MYCN oncogene associated poor clinical outcomes. To better understand underlying mechanisms aggressive neuroblastoma, our group incorporated patient-relevant loss-of-function mutations into established MYCN-driven zebrafish model...